Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ketone supplement shows promise for brain fog in early memory loss

NCT ID NCT06962501

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested whether a single dose of an oral ketone supplement could increase blood flow and improve brain connectivity in 15 older adults with subjective or mild cognitive decline. Participants had one 2-hour session including MRI scans and cognitive tests. The goal is to see if this supplement might help support brain health in early memory problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral ketone monoester supplement
What this could lead to
If it works, this could point toward a simple dietary supplement that temporarily improves brain function in people with early memory problems.
What could go wrong
This is a very small, early pilot study with only 15 participants and a single dose. Results may not apply to long-term use or to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Apr 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 55 years or older * Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI) SCD CRITERIA: * Self-experienced, persistent decline of cognitive abilities within the last 5 years in relation to a previously normal status * Normal results on demographically adjusted standardized cognitive tests * Accompanied by concerns associated with SCD and a feeling of worse performance than others in the same age group * Decline must not be related to a specific event or explained by a specific disease, medical disorder, medication, or substance abuse MCI CRITERIA * Fulfils criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5): * Demographically adjusted performance between -1 and -2 SD below average in one or more cognitive domains on standardized cognitive tests * Accompanied by concern from the individual, a knowledgeable informant, or clinician indicating mild cognitive decline * Capacity for independent daily activities is maintained Exclusion Criteria: * Clinical diagnoses of psychiatric disorders (e.g., anxiety disorders, depression) * Diagnosed major neurocognitive disorder (i.e., dementia) * Association of SCD or MCI with delirium * Diagnosed cardiometabolic disease (Uncontrolled hypertension (systolic blood pressure \>160 mm Hg, and/or diastolic blood pressure \>100 mm Hg, Type 2 diabetes) * Substance use disorder * History of heart attack or stroke requiring hospitalization in the past 3 years * MRI contraindications, including implanted medical devices * Experiencing residual fatigue, brain fog, or tiredness post-acute illness (i.e., long-COVID) * Severe literacy, visual, hearing, and/or speech impairment that would make participation in the study difficult or impossible * Individuals who are not fluent in Swiss German or German

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCI are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital of Basel

    Basel, Canton of Basel-City, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.